Summary:
In 302 adults with T2D (HbA1c 7.0-10.0%) on stable SGLT2 inhibitor (± metformin) for ≥90 days, semaglutide escalated to 1.0 mg weekly for 30 weeks reduced HbA1c by additional 1.42% vs placebo, weight by additional 3.81 kg, and 79% achieved <7.0% vs 20% compared to volume-matched placebo continuing background SGLT2i ± metformin, with more GI adverse events (37% vs 13%) leading to 4.3% discontinuation.
| PICO | Description |
|---|---|
| Population | 302 adults with T2D (HbA1c 7.0-10.0%) on stable SGLT2i ± metformin ≥90 days. |
| Intervention | Semaglutide titrated to 1.0 mg weekly for 30 weeks total. |
| Comparison | Volume-matched placebo continuing background SGLT2i ± metformin. |
| Outcome | Additional HbA1c -1.42%. Weight -3.81 kg. Target <7%: 79% vs 20%. |
Semaglutide added to SGLT2i (SUSTAIN 9)
RCT · type 2 diabetes · 30 weeks
Adding semaglutide to an SGLT2 inhibitor gave a further 1.42% HbA1c drop and 3.81 kg weight loss, with nearly 80% reaching target. More GI events but no new safety signals.
Clinical Context
GLP-1 RA + SGLT2i combination leverages complementary mechanisms: glycosuria/natriuresis + appetite suppression/insulin enhancement.
Clinical Pearls
1. Additive Benefits Confirmed: 1.42% additional HbA1c reduction and 3.81 kg weight loss despite already on SGLT2i.
2. High Target Achievement Rate: Nearly 80% vs 20% achieved <7.0%.
3. Complementary Mechanisms Enhance Weight Loss: Both classes promote weight loss differently.
4. No Unexpected Safety Signals: Known class effects without dangerous interactions.
Practical Application
Maintain SGLT2i while titrating semaglutide. Monitor for volume depletion especially with diuretics or reduced kidney function.
Study Limitations
30-week duration. Not powered for CV/renal outcomes. Different SGLT2is permitted. Only 1.0 mg semaglutide dose.
Bottom Line
Adding semaglutide to SGLT2i produces substantial additional glycemic and weight benefits, supporting combination therapy for comprehensive cardiometabolic protection.
Source: Zinman B, et al. “Semaglutide as Add-on to SGLT2i Therapy (SUSTAIN 9).” Lancet Diabetes Endocrinol, 2019. Read article